Citadel Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $673K | Sell |
24,900
-21,700
| -47% | -$729K | ﹤0.01% | 8580 |
|
|
2025
Q4 | $2M | Buy |
46,600
+22,700
| +95% | +$856K | ﹤0.01% | 5914 |
|
|
2025
Q3 | $677K | Buy |
23,900
+9,500
| +66% | +$284K | ﹤0.01% | 8409 |
|
|
2025
Q2 | $270K | Sell |
14,400
-400
| -3% | -$7.58K | ﹤0.01% | 10045 |
|
|
2025
Q1 | $266K | Sell |
14,800
-5,200
| -26% | -$106K | ﹤0.01% | 9848 |
|
|
2024
Q4 | $336K | Buy |
20,000
+6,890
| +53% | +$132K | ﹤0.01% | 9421 |
|
|
2024
Q3 | $212K | Buy |
13,110
+330
| +3% | +$3.88K | ﹤0.01% | 10022 |
|
|
2024
Q2 | $105K | Buy |
12,780
+4,230
| +49% | +$44.3K | ﹤0.01% | 10842 |
|
|
2024
Q1 | $127K | Sell |
8,550
-15,740
| -65% | -$212K | ﹤0.01% | 11031 |
|
|
2023
Q4 | $352K | Buy |
24,290
+110
| +0.5% | +$1.13K | ﹤0.01% | 8824 |
|
|
2023
Q3 | $261K | Buy |
24,180
+1,540
| +7% | +$18.5K | ﹤0.01% | 9414 |
|
|
2023
Q2 | $292K | Buy |
22,640
+1,370
| +6% | +$18.5K | ﹤0.01% | 9104 |
|
|
2023
Q1 | $281K | Buy |
21,270
+2,560
| +14% | +$40.7K | ﹤0.01% | 9506 |
|
|
2022
Q4 | $281K | Buy |
18,710
+5,920
| +46% | +$54.3K | ﹤0.01% | 9459 |
|
|
2022
Q3 | $151K | Buy |
12,790
+1,330
| +12% | +$18K | ﹤0.01% | 10693 |
|
|
2022
Q2 | $130K | Buy |
11,460
+2,770
| +32% | +$55.6K | ﹤0.01% | 11133 |
|
|
2022
Q1 | $260K | Buy |
8,690
+4,700
| +118% | +$127K | ﹤0.01% | 10917 |
|
|
2021
Q4 | $106K | Sell |
3,990
-2,500
| -39% | -$75.4K | ﹤0.01% | 12664 |
|
|
2021
Q3 | $236K | Buy |
6,490
+820
| +14% | +$32.3K | ﹤0.01% | 11605 |
|
|
2021
Q2 | $246K | Buy |
5,670
+1,300
| +30% | +$49.1K | ﹤0.01% | 11730 |
|
|
2021
Q1 | $149K | Buy |
4,370
+560
| +15% | +$22.2K | ﹤0.01% | 12042 |
|
|
2020
Q4 | $133K | Sell |
3,810
-760
| -17% | -$22K | ﹤0.01% | 10025 |
|
|
2020
Q3 | $110K | Buy |
+4,570
| New | +$112K | ﹤0.01% | 9223 |
|
|
2020
Q2 | – | Sell |
-1,160
| Closed | -$18K | – | 10391 |
|
|
2020
Q1 | $18K | Buy |
+1,160
| New | +$24.7K | ﹤0.01% | 9325 |
|
|
2019
Q4 | – | Sell |
-1,260
| Closed | -$24K | – | 9652 |
|
|
2019
Q3 | $24K | Sell |
1,260
-7,800
| -86% | -$161K | ﹤0.01% | 8898 |
|
|
2019
Q2 | $236K | Buy |
9,060
+6,300
| +228% | +$142K | ﹤0.01% | 7946 |
|
|
2019
Q1 | $71K | Buy |
+2,760
| New | +$63.1K | ﹤0.01% | 8680 |
|
|
2018
Q2 | – | Sell |
-2,770
| Closed | -$98K | – | 9211 |
|
|
2018
Q1 | $98K | Buy |
+2,770
| New | +$111K | ﹤0.01% | 7722 |
|
|
2016
Q4 | – | Sell |
-1,790
| Closed | -$66K | – | 7746 |
|
|
2016
Q3 | $66K | Buy |
+1,790
| New | +$51.3K | ﹤0.01% | 6786 |
|
|
2016
Q1 | – | Sell |
-120
| Closed | -$4K | – | 7769 |
|
|
2015
Q4 | $4K | Buy |
120
+70
| +140% | +$2.12K | ﹤0.01% | 8495 |
|
|
2015
Q3 | $1K | Sell |
50
-90
| -64% | -$2.69K | ﹤0.01% | 8787 |
|
|
2015
Q2 | $4K | Buy |
+140
| New | +$5.35K | ﹤0.01% | 8566 |
|
|
2014
Q4 | – | Sell |
-280
| Closed | -$5K | – | 8692 |
|
|
2014
Q3 | $5K | Buy |
280
+140
| +100% | +$3.96K | ﹤0.01% | 7919 |
|
|
2014
Q2 | $5K | Sell |
140
-240
| -63% | -$8.16K | ﹤0.01% | 7727 |
|
|
2014
Q1 | $15K | Sell |
380
-120
| -24% | -$4.28K | ﹤0.01% | 7387 |
|
|
2013
Q4 | $14K | Buy |
500
+120
| +32% | +$3.52K | ﹤0.01% | 6626 |
|
|
2013
Q3 | $14K | Sell |
380
-2,210
| -85% | -$80.7K | ﹤0.01% | 6372 |
|
|
2013
Q2 | $87K | Buy |
+2,590
| New | +$117K | ﹤0.01% | 5316 |
|
Other funds holding RIGL
AC
VCM
Citadel Advisors's RIGL Position: Q1 2026 in Review
Citadel Advisors reduced its Rigel Pharmaceuticals (RIGL) stake by 29% in Q1 2026, selling an estimated $1.82M and leaving 131,199 shares worth $3.55M. The position accounts for ﹤0.01% of the portfolio, ranked #4935.
Citadel Advisors first reported a position in RIGL in Q2 2013 and has held it in 48 quarters since. The position peaked at $22.2M in Q4 2020. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.
- Citadel Advisors held 131,199 shares of Rigel Pharmaceuticals worth $3.55M as of Q1 2026.
- Citadel Advisors sold 54,220 Rigel Pharmaceuticals shares in Q1 2026, an estimated $1.82M.
- Rigel Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4935 holding.
- Citadel Advisors first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 48 quarters since.
- Citadel Advisors's Rigel Pharmaceuticals position peaked at $22.2M in Q4 2020.
- 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.